A new JAK in­hibitor earns FDA nod in myelofi­bro­sis, set­ting up a fight with In­cyte, Bris­tol My­ers

The FDA on Tues­day hand­ed down an ac­cel­er­at­ed ap­proval for CTI Bio­Phar­ma’s JAK in­hibitor Von­jo (pa­cri­tinib) to treat in­ter­me­di­ate or high-risk pri­ma­ry or sec­ondary myelofi­bro­sis …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER